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Silent Progression in Disease
Activity–Free Relapsing Multiple Sclerosis
University of California, San Francisco MS-EPIC Team, Bruce A. C. Cree, MD, PhD, MAS,
Jill A. Hollenbach, PhD, MPH, Riley Bove, MD, MMSc, Gina Kirkish, MSc,
Simone Sacco, MD, Eduardo Caverzasi, MD, PhD , Antje Bischof, MD , Tristan Gundel,
Alyssa H. Zhu, MSc, Nico Papinutto, PhD, William A. Stern, Carolyn Bevan, MD, MS,
Andrew Romeo, MD, Douglas S. Goodin, MD, Jeffrey M. Gelfand, MD, MAS,
Jennifer Graves, MD, PhD, MAS, Ari J. Green, MD, MAS, Michael R. Wilson, MD, MAS,
Scott S. Zamvil, MD, PhD, Chao Zhao, MSc, Refujia Gomez, Nicholas R. Ragan,
Gillian Q. Rush, Patrick Barba, Adam Santaniello, Sergio E. Baranzini, PhD,
Jorge R. Oksenberg, PhD, Roland G. Henry, PhD, and Stephen L. Hauser, MD
Objective: Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially
lower in actively treated patients compared to natural history studies from the pretreatment era. Nonetheless, in our
recently reported prospective cohort, more than half of patients with relapsing MS accumulated significant new disabil-
ity by the 10th year of follow-up. Notably, “no evidence of disease activity” at 2 years did not predict long-term stabil-
ity. Here, we determined to what extent clinical relapses and radiographic evidence of disease activity contribute to
long-term disability accumulation.
Methods: Disability progression was defined as an increase in Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5
(or greater) from baseline EDSS = 0, 1.0–5.0, and 5.5 or higher, respectively, assessed from baseline to year 5 (1 year)
and sustained to year 10 (1 year). Longitudinal analysis of relative brain volume loss used a linear mixed model with sex,
age, disease duration, and HLA-DRB1*15:01 as covariates.
Results: Relapses were associated with a transient increase in disability over 1-year intervals (p = 0.012) but not with
confirmed disability progression (p = 0.551). Relative brain volume declined at a greater rate among individuals with
disability progression compared to those who remained stable (p < 0.05).
Interpretation: Long-term worsening is common in relapsing MS patients, is largely independent of relapse activity,
and is associated with accelerated brain atrophy. We propose the term silent progression to describe the insidious dis-
ability that accrues in many patients who satisfy traditional criteria for relapsing–remitting MS.
ANN NEUROL 2019;85:653–666
One of the defining clinical features for many multiplesclerosis (MS) patients is relapses—episodes of neuro-
logical worsening that evolve over hours or days and then last
for days or weeks, followed by varying degrees of recovery.1
MS relapses are typically accompanied by radiographic
changes on magnetic resonance imaging (MRI) such as the
development of new lesions on T2-weighted imaging or new
contrast-enhancing lesions.2 Relapses contribute to meaning-
ful neurological disability over the short term3; however,
whether relapses also contribute substantially to long-term
disability is controversial. Some observational studies found
no substantial impact of relapses on long-term disability
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progression in participants who had reached specific MS
milestones.4–7 In contrast, natural history studies suggest
that relapse frequency and recovery from relapses within the
first few years of disease onset contribute to long-term
disability.8–12 A recent study using the large MSBase dataset
found that relapses contribute, at least in part, to long-term
disability.13 The generally accepted model of MS disability
proposes a 2-stage process in which poor recovery from
relapses underlies disability progression during the relapsing
phase of MS, which is followed by insidious decline in func-
tion caused by neurodegeneration in the secondary progres-
sive disease phase.14 Whether the radiographic counterparts
of MS relapses documented by the occurrence of new T2
lesions or gadolinium-enhancing lesions seen on brain MRI
also contribute to long-term disability is also controversial.
Some studies have showed that the number of lesions seen
on initial brain MRI or evolution of new lesions following
relapsing disease onset correlate with long-term disability,15,16
whereas others point to a clinicoradiological paradox inherent
in MS—that the radiographic burden of tissue injury corre-
lates poorly with disability worsening.17,18 A methodological
limitation to studies that have investigated the contributions
of relapsing activity to long-term disability is patient retention.
Many studies, including long-term follow-up studies from
clinical trial cohorts, are difficult to interpret because substan-
tial proportions of participants are lost to follow-up (33–59%
retention)19–25 or because interval data are missing. We
sought to test the 2-stage hypothesis of disability progression
by defining the contribution of relapses and radiographic dis-
ease activity to long-term disability and brain atrophy using
a well-phenotyped, University of California, San Francisco
(UCSF) MS-EPIC (expression/genomics, proteomics, imag-
ing, and clinical) dataset.
The MS-EPIC dataset is a single-center prospective
observational cohort of contemporary, actively treated MS
patients who have been evaluated annually since July 2004
with long-term data ascertained in 91% of study partici-
pants. We previously reported that rates of worsening and
evolution to secondary progressive MS (SPMS) were sub-
stantially lower when compared to natural history studies
from the pretreatment era. Nonetheless, more than half of
patients with relapsing MS accumulated significant new dis-
ability after 1 decade of follow-up.26 Notably, no evidence
of disease activity (NEDA) at 2 years did not predict long-
term stability. Because over half of the relapsing–remitting
(RRMS) patients in the EPIC dataset developed clinically
significant disability worsening by 10 years, but were still
considered by their treating physicians to have relapsing
MS (ie, they had not been reclassified as having developed
secondary progressive disease), we sought to determine
whether ongoing relapse activity, assessed clinically as
relapses or radiographically as new or enlarging focal white
matter lesions, might be the primary contributor to this
long-term disability worsening. We also sought to deter-
mine to what extent relapsing activity contributes to evolu-
tion of brain atrophy—an in vivo measure of irreversible
tissue injury that correlates with long-term disability.
Patients and Methods
The UCSF EPIC cohort is a prospective, longitudinal,
actively treated, single-center cohort of patients, now in its
14th year of follow-up. The UCSF Institutional Review
Board reviewed and approved the study protocol. Written
informed consent was obtained for all participants. This
study was conducted in accordance with the Declaration of
Helsinki. The 10-year, postbaseline follow-up of this cohort
was previously reported.26 Although the cohort enrolled par-
ticipants with clinically isolated syndrome (CIS), RRMS,
SPMS, and primary progressive MS, here we considered
only those participants who had either CIS or RRMS at
entry. For baseline data, the annualized relapse rate (ARR;
life-time) was calculated from when the first relapse occurred
to baseline in the patient self-reported database. At end of
study, the ARR was calculated from baseline to last visit. If
missing data were due to MS disability in Multiple Sclerosis
Functional Composite (MSFC) assessment, then 99 seconds
was used in the Timed 25-Foot Walk (T25FW), 300 sec-
onds was used in the 9-Hole Peg Test (9HPT), and 0 scores
were used for the 3-second Paced Auditory Serial Addition
Test (PASAT) and the Symbol Digit Modalities Test
(SDMT). R median algorithm (type 7) was used to calculate
median and interquartile scores. Some patients had partial
visits due to missing MSFC at last follow-up. In this case,
the most recent available MSFC visit was used.
As previously reported,26 clinically significant disability
was defined as worsening by an increase in the Expanded
Disability Status Scale (EDSS)27 of 1.5 points if the baseline
EDSS score was 0, 1.0 point if the baseline EDSS score was
between 1.0 and 5.0, and 0.5 point for baseline EDSS
scores of 5.5 or higher. Relapses were patient-reported and
assessed systematically for the year prior at each annual visit.
Relapses were defined as new, focal neurological symptoms
evolving over days to weeks that lasted for >24 hours, were
not associated with an intercurrent infection, and were typi-
cally followed by at least partial recovery of function over
time. Examples of relapses included vision loss, double vision,
weakness in one or more limbs, sensory disturbances includ-
ing paresthesias, or loss of coordination including imbalance.
Symptoms that were nonspecific such as headache, malaise,
and generalized weakness or were insidious and progressive in
nature were not considered relapses. To assess the effect
of relapses on disability, we compared 1-year intervals, with
disability assessments performed annually. For each 1-year
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interval, a short-term impact of relapse on MS disability was
defined as an increase in EDSS between the 2 annual visits
during a year in which a relapse occurred. As such, each sub-
ject was considered serially for annual assessment of the
impact of relapses on MS disability. Confirmed disability was
defined as worsening maintained for 2 consecutive annual
visits. Lastly, long-term worsening was defined as increase in
disability between baseline and the midpoint of the study
(median years = 5, range = 4–6), with confirmation of wors-
ening 5 years thereafter (sustained worsening).
Disability was also assessed using the T25FW, 9HPT,
and PASAT. Because the SDMT became generally available
for MS studies during the course of the study, this test of
cognitive function was performed after the 5th study year.
Clinically meaningful worsening was defined as a 20%
increase in the T25FW (average of 2 trials), a 20% increase
in the 9HPT time for either arm (single trial), an increase in
the reliable change index for the PASAT, and a 4-point
worsening in the SDMT. The contribution of relapse to dis-
ability was determined by Pearson chi-squared test with
Yates continuity correction or Fisher exact test.
To simplify the analysis of treatment on relapses, we
grouped therapies into 2 tiers: “platform” (eg, interferons,
glatiramer acetate) and “high-potency therapy” (eg, natalizumab,
mitoxantrone, rituximab, cyclophosphamide).26We also consid-
ered a 3-tiered model grouping together therapies by relative
relapse rate reduction: modest (interferons, glatiramer ace-
tate, teriflunomide), moderate (fingolimod, dimethyl fu-
marate), and high (natalizumab, anti-CD20 monoclonal
antibodies, alemtuzumab) efficacy. However, because oral
treatment options and other monoclonal antibodies were not
generally available during the first 6 years of the study, we
present the simpler, 2-tiered model. Multivariate logistic
regression was used to model the impact of treatment tier on
relapses, with disease duration, disease course, and HLA-
DRB1*15:01 included as covariates. HLA-DRB1*15:01 was
included in this and other analyses because we previously
reported an effect of this allele on certain clinical features of
MS.28,29 Age-adjusted baseline brain volume was calculated
by regression (baseline brain volume ~ age + sex + disease
duration) and was divided into quartiles. Logistic regression
was used to assess relationships between long-term disability
worsening and age-adjusted brain volume. A linear mixed
model was developed to consider the impact of relapses and
disability worsening on relative brain volume loss. Four
subject groups were considered: (1) participants with
increased disability but without relapses, (2) participants
without increased disability and without relapses, (3) partici-
pants with increased disability and with relapses, and
(4) participants without increased disability but with
relapses. The annual percentage change in relative brain vol-
ume is defined as the slope of follow-up year divided by the
relative brain volume at baseline. If brain volume is a0 and
cerebrospinal fluid (CSF) is b0 at time 0, and brain volume is
a10 and CSF is b10 at time 10, then the percentage change of
brain volume is (a10 − a0) / 10 / a0 = a10−a010a0 . The percent
change of relative brain volume is (a10 / [a10 + b10] − a0 /
[a0 + b0]) / 10 / (a0 / [a0 + b0]) = a10b0−a0b1010a0 a10 + b10ð Þ. The ratio of
percentage change of brain volume to the percentage
change of relative brain volume is (a10 − a0)(a10 + b10) /
(a10b0 − a0b10). In this dataset, the ratio of relative brain vol-
ume to percentage change in brain volume is 5- to 6-fold.
To assess the effect of new brain lesions on silent pro-
gression and on brain atrophy in treated and untreated partici-
pants, 4 subgroups were identified: (1) treated participants
without new lesions (new T2 or Gd+), (2) treated participants
with new lesions, (3) untreated participants without new
lesions, and (4) untreated participants with new lesions. Logis-
tic regression was used to identify influences on disability and
a linear mixed model for brain atrophy.
The MRI acquisition protocol and analytic pipelines
were previously published.26 Briefly, Lesion Segmentation
Tool30 was used to segment lesion on fluid-attenuated inver-
sion recovery images and corrected using the Mind Control
platform.31 These lesions were used as input to SIENAX32
using optibet33 for brain extraction. Registration and multi-
normal segmentation methods were used to propagate
lesions backward and forward within a subject over time
(unpublished methods). Gadolinium-enhancing lesions were
visually assessed on postcontrast T1-weighted MRI. Gado-
linium was not routinely administered for all brain MRI
studies at long-term follow-up.
Results
Relapses Are Associated with Short-Term but
Not Confirmed or Long-Term Disability
Worsening
The baseline characteristics of this cohort are described in
Table 1. Of 480 RRMS or CIS participants assessed at
baseline, 407 completed visits through year 5  1 year
(43 participants missed this visit, 28 withdrew from the
study, 2 participants died). Of the 43 participants who
missed the year 5 visit 1 year, 33 returned to complete
the year 10 visit. Of the 407 participants who completed
visits through year 5  1 year, 372 subjects completed
the year 10 visit 1 year (19 participants missed this visit,
EDSS was not performed in 1 participant, 14 participants
withdrew from the study, 1 participant died). Therefore,
the percentage of RRMS/CIS participants with baseline
through year 5 and year 10 data was 77.5%. Of 372 long-
term patients with long-term follow-up, 28 (8%) patients
did not have MRI after follow-up year 5 (most recent
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TABLE 1. Baseline Demographic, Clinical, and MRI Features of Relapsing MS at Entry
Characteristic CIS, n = 88 RRMS, n = 392 Total, n = 480
Demographic
Age at entry, yr, mean  SD 41.5  9.6 41.6  9.7 41.6  9.7
Sex, n (%)
Women 59 (67.0) 279 (71.2) 338 (70.4)
Men 29 (33.0) 113 (28.8) 142 (29.6)
Clinical
Disease duration, yr, mean  SD 1.8  3.6 8.9  8.4 7.6  8.2
EDSS score, MIR 1.0 [0.0–1.5] {0–4.0} 1.5 [1.0–2.5] {0–6.5} 1.5 [1.0–2.0] {0–6.5}
MSSS, mean  SD 3.0  2.4 2.5  2.1 2.6  2.2
MSFC, mean  SD
T25FW 11.7  2.2 12.7  2.8 12.5  2.8
9HPT, DH 19.6  4.5 21.2  4.6 20.9  4.7
9HPT, NDH 20.2  3.8 21.8  4.8 21.5  4.7
PASAT-3 49.3  10.8 46.9  10.7 47.3  10.7
Relapse history
ARR, mean  SD 0.5  0.3 0.6  0.5 0.6  0.4
Treatment history, n (%)
Never treated 31 (35.2) 37 (9.4) 68 (14.2)
Not actively treated 29 (33.0) 89 (22.7) 118 (24.6)
Platform therapy 27 (30.7) 261 (66.6) 288 (60.0)
High-potency therapy 1 (1.1) 5 (1.3) 6 (1.2)
MRI, mean  SD
T2 lesion volume, mm3 9.9  14.2 22.8  36.4 20.4  33.8
Number of Gd+ lesions 0.1  0.4 0.4  1.1 0.3  1.0
Total brain volume, cm3 1,550.3  78.2 1,508.1  87.1 1,515.8  87.0
GM volume, cm3 813.6  57.0 797.7  57.9 800.7  58.0
WM volume, cm3 734.9  39.6 708.3  41.9 713.2  42.7
Ventricular CSF volume, cm3 21.7  8.5 27.4  12.5 26.4  12.0
Cortical GM volume, cm3 667.1  48.6 654.3  49.3 656.6  49.4
Genetics
HLA-DRB1*15:01, n (%)
0 copies 52 (59.1) 210 (53.6) 262 (54.6)
1 or 2 copies 36 (40.9) 182 (46.4) 218 (45.4)
Relapsing MS subjects in the EPIC study recruited from July 2004 to December 2008. Subjects were divided into CIS and RRMS
categorized at baseline (2 columns). Treatment type is presented for the year prior to baseline.
9HPT = 9-Hole Peg Test; ARR = annualized relapse rate; CIS = clinically isolated syndrome; CSF = cerebrospinal fluid; DH = dominant
hand; EDSS = Expanded Disability Status Scale; GM = gray matter; MIR = median [interquartile range] {range}; MRI = magnetic reso-
nance imaging; MS = multiple sclerosis; MSFC = Multiple Sclerosis Functional Composite; MSSS = Multiple Sclerosis Severity Scale;
NDH = nondominant hand; PASAT-3 = Paced Auditory Serial Addition Test, 3-second interval; RRMS = relapsing–remitting MS;
SD = standard deviation; T25FW = Timed 25-Foot Walk; WM = white matter.
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scans: baseline only, n = 5; year 1, n = 4; year 3, n = 8;
year 4, n = 10; year 5, n = 1).
Relapse occurrence was associated with clinically mean-
ingful EDSS worsening at the next annual examination;
29.7% of yearly intervals in which participants experienced
relapses were associated with disability worsening at the next
visit, compared to 22.7% of yearly intervals during which
participants did not relapse (odds ratio = 1.44, 95% confi-
dence interval = 1.09–1.90, p = 0.012). However, there was
no impact of relapses on confirmed disability worsening,
defined as disability worsening at the visit following the
relapse and confirmed at the subsequent year; 12.9% of
yearly intervals with relapse, and 14.4% without relapse,
were associated with confirmed worsening (p = 0.551;
Fig 1). Similarly, there was no association between relapses
during the first 6 study years and long-term disability
worsening. For this analysis, long-term follow-up was assessed
at a median of 11 years after baseline (mean = 10.68, stan-
dard deviation = 0.65, minimum = 9 years, maximum = 11
years). In patients with clinically significant long-term disabil-
ity worsening, there was no difference in the proportion of
patients who experienced relapses during the first 6 years of
the study (38.1%) and those who were relapse-free (35.9%,
p = 0.736). The long-term outcomes of the relapsing popula-
tion are summarized in Table 2. Pyramidal and cerebellar
functional scale scores worsened in participants with increased
long-term disability independently of relapse occurrence.
Baseline scores in these scales were not predictive of long-term
outcomes (Supplementary Table 1).
Relapses were associated with short-term worsening
of the T25FW (20% increase) with borderline statistical
significance (p = 0.039; see Fig 1); 9.1% of yearly inter-
vals in which participants experienced a relapse were asso-
ciated with this increase in the T25FW, compared to
5.7% of yearly intervals without relapses. Relapses were
not associated with a significantly confirmed change in the
T25FW or with long-term worsening of the T25FW.
Relapses were not associated with clinically significant
worsening (20% increase) of the 9HPT (see Fig 1); 15.5%
of yearly intervals in which participants experienced a
relapse were associated with a clinically significant increase
in the 9HPT, compared to 11.7% of yearly intervals with-
out relapse (p = 0.091). Similarly, there was no association
between relapses and confirmed change in the 9HPT
(increased in 4.2% of those with relapses vs 3.2% in those
without, p = 0.475) or long-term worsening (p = 0.228).
For the PASAT, 12.6% of annual intervals during
which participants relapsed also experienced short-term wors-
ening on this outcome compared to 11.1% of intervals with-
out relapse (p = 0.500; see Fig 1). There was no discernible
effect of relapses on confirmed worsening of the PASAT
(p = 0.902) or long-term worsening (p = 1.000). Data on
the SDMT were limited to assessments performed after the
5th study year, and no correlation between relapses and subse-
quent worsening on this test was found in the near term
(p = 0.819) or for confirmed worsening (p = 0.755).
Clinical and Genetic Factors Associated with
MS Relapses
Binomial logistic regression was used to assess the associa-
tion of treatment with MS disease-modifying therapies
and relapse occurrence (Table 3). The comparison of SPMS
to RRMS subjects showed a numerically lower risk for
relapse occurrence in SPMS patients, although this compari-
son was not statistically significant. Similarly, the relatively
small group of subjects classified with an unclear disease
course (RRMS patients suspected of transitioning to SPMS)
had a similar risk of relapse as SPMS subjects. Platform
FIGURE 1: Factors that contribute to or correlate with relapse occurrence and the subsequent impact of relapses on disability.
Check marks indicate significant associations, and x marks indicate that associations were not identified. 9HPT = 9-Hole Peg
Test; EDSS = Expanded Disability Status Scale; MRI = magnetic resonance imaging; PASAT = Paced Auditory Serial Addition
Test; SDMT = Symbol Digit Modalities Test; T25FW = Timed 25-Foot Walk.
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TABLE 2. Demographic, Clinical, and MRI Features of Relapsing MS Cohort at Last Visit
Characteristics CIS, n = 13 RRMS, n = 285
SPMS, n = 60 +
Transitional MS, n = 14 Total, n = 372
Demographic
Age at follow-up, mean yr  SD 56.3  8.3 52.5  9.3 59.2  9.1 54.0  9.6
Sex, n (%)
Women 9 (69.2) 199 (69.8) 50 (67.6) 258 (69.4)
Men 4 (30.8) 86 (30.2) 24 (32.4) 114 (30.6)
Years in study, mean  SD 10.5  0.9 10.7  0.7 10.8  0.6 10.7  0.7
Clinical
Disease duration, mean yr  SD 13.8  2.0 19.2  7.8 24.4  9.0 20.1  8.3
EDSS score, MIR 1.5 [1.0–2.5] {0–4.0} 2.0 [1.5–3.0]
{0–7.0}
5.0 [3.5–6.5]
{2.0–8.0}
2.5 [1.5–3.5]
{0.0–8.0}
Δ EDSS mean  SD 0.6  0.7 1.0  1.2 2.5  1.6 1.3  1.4
MSSS, mean  SD 1.5  1.4 1.7  1.2 4.3  2.1 2.2  1.8
MSFC, mean  SD
T25FW 13.1  4.9 12.0  2.1 20.4  14.4 13.6  7.4
9HPT, DH 21.6  8.5 19.7  3.5 28.2  14.3 21.4  7.9
9HPT, NDH 21.0  3.3 20.8  3.4 29.0  13.5 22.4  7.4
PASAT-3 50.6  7.5 51.2  10.6 45.4  13.4 50.1  11.3
SDMT 54.3  11.0 51.2  10.4 40.4  11.4 49.2  11.5
Relapse history
ARR, mean  SD 0.0  0.0 0.1  0.2 0.1  0.2 0.1  0.2
Treatment at last follow-up, n (%)
Never treated 10 (76.9) 32 (11.2) 7 (9.5) 49 (13.2)
Not actively treated 3 (23.1) 107 (37.5) 36 (48.6) 146 (39.2)
Platform therapy 0 (0.0) 76 (26.7) 16 (21.6) 92 (24.7)
High potency 0 (0.0) 70 (24.6) 15 (20.3) 85 (22.9)
MRI, mean  SD
T2 lesion volume, mm3 12.1  17.9 14.3  17.8 19.5  29.5 15.3  20.7
Total brain volume, cm3 1,459.8  70.8 1,433.2  77.0 1,397.5  55.3 1,427.0  74.5
GM volume, cm3 744.8  33.4 734.4  47.6 712.6  33.7 730.5  45.6
WM volume, cm3 715.1  44.5 698.5  41.1 684.7  34.5 696.4  40.4
CSF volume, cm3 28.5  10.0 36.4  16.2 44.0  16.8 37.7  16.5
Cortical GM volume, cm3 593.2  29.5 590.2  41.1 574.2  29.5 587.1  39.2
Genetics
HLA-DRB1*15:01, n (%)
0 copies 6 (46.2) 153 (53.7) 38 (51.4) 197 (53.0)
1 or 2 copies 7 (53.8) 132 (46.3) 36 (48.6) 175 (47.0)
Subjects were divided into CIS, RRMS, SPMS, or transitional categories at last follow-up. The transitional category refers to patients who
remain classified as having RRMS and in whom transition to SPMS is suspected but has not been confirmed. Δ EDSS was calculated from
baseline to last visit. Treatment type is shown for the year preceding the last follow-up visit.
9HPT = 9-Hole Peg Test; ARR = annualized relapse rate; CIS = clinically isolated syndrome; CSF = cerebrospinal fluid; DH = dominant hand;
EDSS = Expanded Disability Status Scale; GM = gray matter; MIR = median [interquartile range] {range} calculated using R median algorithm,
type 7; MRI = magnetic resonance imaging; MS = multiple sclerosis; MSFC = Multiple Sclerosis Functional Composite; MSSS = Multiple Scle-
rosis Severity Scale; NDH = nondominant hand; PASAT-3 = Paced Auditory Serial Addition Test, 3-second interval; RRMS = relapsing–
remitting MS; SD = standard deviation; SDMT = Symbol Digit Modality Test; SPMS = secondary progressive MS; T25FW = Timed 25-Foot
Walk; WM = white matter.
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therapies were 2.4-fold more likely to be associated with
relapses compared to high-potency therapies. The major MS
susceptibility allele, HLA-DRB1*15:01, was associated with
an increased risk of relapse albeit with marginal statistical
significance, suggesting a potential genetic contribution to
relapses, although the relatively small sample size limited
analysis of copy number. Thus, a longer disease duration, a
secondary progressive versus relapsing disease course, treat-
ment with disease-modifying therapies, and absence of the
HLA-DRB1*15:01 allele were associated with lower relapse
risk (see Fig 1), although the overall model accounts for only a
fraction of relapse variance (McFadden pseudo-R2 = 0.034).
Remarkably, factor analysis (analogous to principal compo-
nent analysis but with both continuous and categorical vari-
ables contributing to individual clusters) of these mixed data
showed that participants clustered together by annual relapse
frequency based on the clinical and genetic factors listed in
Table 3 (Fig 2). That subjects who are grouped together by
commonality of these factors also share similar numbers of
relapses suggests that the variables identified in the binomial
logistic regression are biologically relevant contributors to
relapse occurrence.
White Matter Lesions Contribute to MS Relapses
As expected, radiographic disease activity as defined by new
brain lesions on T2-weighted imaging correlated strongly with
clinical relapses (see Fig 1). New lesions (defined as T1
gadolinium–diethylenetriamine pentaacetic acid enhancing
lesions or new T2 lesions) were detected in 47.1% of annual
intervals during which participants relapsed, compared with
25.3% of annual intervals without relapse (p = 4.0 × 10−16).
However, the development of new T2 lesions did not corre-
late with EDSS worsening measured at the next annual visit
(p = 0.521), with confirmed worsening (p = 0.430), or with
long-term worsening (p = 0.116).
TABLE 3. Binomial Logistic Regression of Relapse:
Relapse Occurrence ~ Disease Duration + Disease
Course + Treatment + HLA-DRB1*15:01
Odds Ratio 95% CI p
Intercept 0.11 0.06–0.20 <0.001
Disease duration 0.96 0.94–0.98 <0.001
Disease course
Disease course,
SPMS/RRMS
0.59 0.26–1.18 0.167
Disease course,
UNC/RRMS
0.62 0.03–3.18 0.647
Treatment, platform/
high potency
2.41 1.45–4.27 0.001
DRB1*15:01,
1 or 2 copies/none
1.33 1.01–1.76 0.041
Binomial logistic regression was performed with relapse occurrence as the
outcome and with disease duration, disease course, treatment, and
HLA-DRB1*15:01 as predictors. For disease duration, the odds ratio is
for each year; the longer the disease duration, the lower the relapse risk.
Subjects classified with CIS at baseline who remained CIS at the last
observation were not analyzed, because by definition, these subjects expe-
rienced only one relapse.
CI = clinically isolated syndrome; CIS = clinically isolated syndrome;
MS = multiple sclerosis; RRMS = relapsing remitting MS; SPMS = sec-
ondary progressive MS; UNC = unclear, subjects who were transitioning
from RRMS to SPMS.
FIGURE 2: Factor analysis for mixed data clustering individuals by shared clinical and genetic attributes (from Table 3) that
contribute to relapse frequency. Participants appear to cluster together based on annual relapse frequency. Participants with no
relapses cluster separately from participants with more than one relapse. Even participants with a single relapse appear to
cluster together as a subset of participants with no relapses.
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Long-Term Brain Volume Loss and Disability
Progression
The relationship between relapses, disability progression,
and changes in relative brain volume was assessed using a
linear mixed-effects model in the 4 subject groups that were
defined by the presence or absence of relapse and/or
increased disability (Table 4). At baseline, a significant
effect on relative brain volume loss was observed only in
the group of subjects with worsening disability and relapses.
Age at baseline, disease duration at baseline, male sex, and
years of follow-up were all associated with decline in relative
brain volume loss. The interaction term of subject group
with years of observation in the study was significant for all
3 groups relative to the reference group of clinically stable
participants (without disability worsening and without
relapses). This interaction term indicates that each subject
group modifies the impact of time on relative brain volume
loss. That the interaction terms for all groups relative to clini-
cally stable patients (those without worsening disability and
without relapses) was significant indicates that patient group
modifies the effect of time on relative brain volume loss.
Therefore, the rates of relative brain volume loss for partici-
pants with either relapses or increasing disability are signifi-
cantly greater than the rate found in clinically quiescent
participants (Fig 3, Table 5). Significant differences were
found for comparisons between the “stable disability without
relapse” and “increased disability without relapse,” “increased
disability with relapse,” and “stable disability with relapse”
groups, but no differences were observed for other compari-
sons. The most statistically significant comparison is for the
group of subjects who experienced increased disability with-
out relapse in comparison to the group of subjects who were
clinically stable. Nonsignificant p values suggest that there is
no difference between the 2 groups being compared on rates
of relative brain volume loss. Although relapses may contrib-
ute to relative brain volume loss in subjects without increas-
ing disability (p = 0.027), there was no apparent additional
impact of relapses in the group of subjects with worsening
disability (p = 0.486). Similarly, there was no apparent addi-
tional impact of increased disability in the group of subjects
with relapses (p = 0.999).
The baseline brain parenchymal fraction was not sig-
nificantly different between the 4 groups, and, over the
course of the study, brain volume declined in each group.
In considering the group of patients who did not experi-
ence relapses during the first 6 years of the study, relative
brain volume declined at a more pronounced rate in partic-
ipants whose disability progressed compared to those who
remained stable (see Fig 3). Among these nonrelapsing par-
ticipants, CSF volume marginally increased in participants
who experienced long-term increased disability (p = 0.022,
nonsignificant following multiple comparison correction).
Changes in T2 lesion volume, white matter volume, gray
matter volume, cortical gray matter volume, and brain vol-
ume were similar between these 2 groups.
Baseline Brain Volume and Disability Progression
Several models were developed to determine whether greater
baseline age-adjusted brain atrophy placed participants at
greater risk for disability. Results indicated that age-adjusted
baseline brain atrophy was associated with both an increased
risk of long-term disability (Supplementary Table 3) and silent
progression (Supplementary Table 4). By contrast, the occur-
rence of relapses did not appear to worsen the risk of long-
TABLE 4. Multivariate Regression Model of Relative
Brain Volume over Time: Relative Brain Volume ~
Group + Year of Follow-up + Group * Year of
Follow-up + Sex + HLA-DRB1*15:01 + Age at
BL + Disease Duration at BL
Effect Estimate SE p
Intercept 0.9952 0.001717 <0.0001
Increased disability
without relapse
−0.00064 0.001003 0.5253
Stable disability with
relapse
−0.00100 0.000837 0.2310
Increased disability
with relapse
−0.00215 0.000950 0.0245
Year of follow-up −0.00066 0.000042 <0.0001
Year of follow-up *
increased disability
without relapse
−0.00018 0.000069 0.0094
Year of follow-up *
stable disability with
relapse
−0.00013 0.000058 0.0267
Year of follow-up *
increased disability
with relapse
−0.00013 0.000064 0.0470
Age at BL −0.00021 0.000038 <0.0001
Disease duration at
BL
−0.00021 0.000044 <0.0001
Sex, men −0.00195 0.000668 0.0038
DRB1*15:01 −0.00093 0.000625 0.1388
Linear mixed model of measures of relative brain volume over time. The
group of patients with stable Expanded Disability Status Scale and with-
out prior relapses is used as reference for the other 3 groups. Relative
brain volume is defined as brain volume/(brain volume + cerebrospinal
fluid volume). HLA-DRB1*15:01: either 1 or 2 copies.
BL = baseline; SE = standard error.
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term disability (see Supplementary Table 3) or recovery from
relapses (Supplementary Table 5).
Associations with Treatment
To control for potentially deleterious effects of treatment
on brain volume loss, we first assessed the impact of plat-
form therapies versus no treatment on brain volume loss
(Supplementary Table 2a) and then assessed the impact of
treatment escalation to natalizumab (Supplementary Table 2b),
the most commonly used escalation therapy in this dataset, on
brain volume loss using linear mixed models. These analyses
showed that treatment with platform therapy reduced brain
atrophy and that escalation to natalizumab is potentially associ-
ated with further stabilization of brain volume loss despite
natalizumab-treated participants having lower baseline brain
volumes, which we interpret as a marker of disease severity.
Of the 138 participants who experienced disability
worsening, 46 were clinically recognized as having devel-
oped or developing SPMS, whereas the remaining 92 were
considered still having a RRMS disease course at the time
of the last observation. Of these 92 RRMS participants,
34 experienced long-term disability worsening without
relapse. In comparison to these 34 participants who expe-
rienced progression that was not clinically recognized, the
patients who developed clinically recognized SPMS scored
higher on the EDSS and Multiple Sclerosis Severity Score
and had longer disease durations at baseline (Table 6).
However, there was no difference in rates of brain volume
FIGURE 3: Relative brain atrophy is attenuated in clinically stable patients. Longitudinal response plots show the impact of
relapses and disability on relative brain volume loss. Plots of individual data are depicted in addition to the regression lines that
are adjusted for covariates (sex, disease duration, age, and HLA-DRB1*15:01). CSF = cerebrospinal fluid.
TABLE 5. Comparison of Relative Brain Loss by Group
Increased Disability
without Relapse
Stable Disability
without Relapse
Increased Disability
with Relapse
Stable Disability
with Relapse
Increased disability without relapse — — — —
Stable disability without relapse 0.009 — — —
Increased disability with relapse 0.486 0.047 — —
Stable disability with relapse 0.449 0.027 0.999 —
Pairwise comparisons of slopes of relative brain volume loss across the 4 groups.
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loss or T2 burden of disease between the participants with
disability worsening who were classified as having SPMS
versus those who remained classified as having RRMS,
suggesting an underlying physiologic/anatomic similarity. In
contrast, participants with silent progression had lower EDSS
scores at baseline and a shorter disease duration, yielding a
difference in the baseline Multiple Sclerosis Severity Score.
Logistic regression was used to analyze whether the
development of new lesions in treated and untreated par-
ticipants was associated with long-term disability worsen-
ing (Supplementary Table 6a). Although statistically
significant effects were not observed for any subgroup, this
analysis suggested that participants with new lesions could
be at increased risk for long-term disability independent of
treatment.
A linear mixed model was used to assess whether
new brain lesions in treated and untreated participants
influenced brain atrophy. Rates of relative brain volume
loss were comparable across these 4 groups without a
trend to suggest that new lesions influenced long-term
brain atrophy (Supplementary Table 6b).
Sensitivity Analyses
To address potential confounding by inclusion of CIS
subjects who remained stable over the long term, we
repeated our analyses excluding these subjects. Excluding
stable CIS subjects (n = 13) did not significantly alter the
observations regarding the short-term and long-term
impact of relapses on disability (Supplementary Table 7a).
Similarly, excluding stable CIS participants did not influ-
ence the multivariate regression model of relative brain
volume over time (Supplementary Table 7b).
Discussion
These data reveal that long-term worsening is common in
RRMS patients and is largely independent of relapses or
new lesion formation on brain MRI. Thus, insidious
progression accrues in many early RRMS patients who
remain classified as having relapsing MS. The current defi-
nition of SPMS is worsening of disability independent of
relapses over at least a 6-month interval. Our data suggest
that this process occurs earlier than is clinically recognized
by either patients or physicians; 92 of the 138 patients
who experienced insidious worsening of clinically mean-
ingful disability in this dataset were still considered by
their clinicians to have RRMS. It is possible that the loss
of function over time is so gradual as to be unnoticed by
the patient or physician. Typically, these patients have low
EDSS scores and are for the most part fully functional.
Many clinicians do not consider a diagnosis of SPMS in
patients with EDSS scores of 3 or less. The recently
TABLE 6. Comparison of SPMS versus RRMS with Silent Progression: MRI Markers ~ Group (SPMS vs Silent
Progression) + Visit Type + Group * Visit Type + Sex + HLA-DRB1*15:01 + Age at BL + Disease Duration at BL
SPMS Silent Progression p
Brain atrophy (95% CI) −7.432 (−8.965, −5.899) −8.595 (−10.316, −6.874) 0.322
WMV atrophy (95% CI) −1.715 (−2.240, −1.189) −1.984 (−2.566, −1.401) 0.501
GMV atrophy (95% CI) −6.142 (−7.200, −5.084) −6.950 (−8.126, −5.774) 0.316
CGMV atrophy (95% CI) −5.823 (−6.753, −4.894) −6.691 (−7.719, −5.663) 0.219
CSF increase (95% CI) 1.270 (1.072, 1.468) 1.140 (0.925, 1.356) 0.385
T2LV increase (95% CI) −0.321 (−0.741, 0.099) 0.057 (−0.423, 0.537) 0.244
Relative brain atrophy (95% CI) −0.100% (−0.115%, −0.085%) −0.087% (−0.103%, −0.070%) 0.247
EDSS at BL 2.13  1.24 0.60  0.82 3.16 × 10−8
Disease duration at BL, yr 12.72  9.57 7.76  8.03 0.019
MSSS at BL 2.49  2.11 1.25  1.63 0.006
Age at onset, yr 34.38  9.92 34.26  8.40 0.956
Linear mixed model of measures of brain and lesion volume over time comparing participants who developed clinically definite SPMS versus those
RRMS participants with silent progression. The values presented are the coefficients of the effect of time on the parameter observed. For brain atrophy,
WMV, GMV, CGMV, CSF, and T2LV, the unit of measure is cm3 per year. For relative brain volume, the percentage change is presented.
BL = baseline; CGMV = cortical gray matter volume; CI = confidence interval; CSF = cerebrospinal fluid; EDSS = Expanded Disability Status
Scale; GMV = gray matter volume; MRI = magnetic resonance imaging; MS = multiple sclerosis; MSSS = Multiple Sclerosis Severity Scale;
RRMS = relapsing–remitting MS; SPMS = secondary progressive MS; T2LV = T2 lesion volume; WMV = white matter volume.
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suggested MSBase definition of SPMS requires a minimum
EDSS score of 4.0.34 The EDSS is nonlinear, and patients
with scores <3 are less likely to show more year-to-year
changes than those with scores between 3 and 6. Moreover,
during the relapsing phase, disability measures are con-
founded by clinical attacks followed by variable recovery.
All of these factors can obscure recognition of an underly-
ing neurodegenerative process that we labeled silent progres-
sion to highlight its subtle emergence over the course of
RRMS. It seems likely that the same underlying process
that causes silent progression is responsible for SPMS when
the march of clinical worsening is more evident. In this
regard, it is notable that patients experiencing silent pro-
gression had accelerated brain atrophy over the long-term
course of the EPIC study, as well as more age-adjusted
brain atrophy at the time of their initial enrollment.
Our data are consistent with 2 simultaneous pro-
cesses; one results in the appearance of new focal demye-
linating lesions visible on brain MRI that correlate with
relapses, and the other is more diffuse and contributes to
brain atrophy. This second process of global tissue injury
is largely independent of relapses or focal lesion formation
and appears to represent the most important contributor
to long-term MS disability. That brain volume loss occurs
early in MS and correlates with long-term disability was
shown in prior studies.35–37 However, uncertainty remains
as to whether this process is dependent or independent of
the development of new focal lesions. Because we found
no correlation of new brain MRI lesions with long-term
disability, our data are more consistent with the hypothe-
sis that either diffuse injury or perhaps focal lesions too
small to be detected by current methods lead to irrevers-
ible tissue loss.
The pathologic substrate responsible for progressive tis-
sue injury in MS is likely to result from some combination of
a white matter axonopathy and direct neuronal injury. Slowly
enlarging white matter lesions associated with chronic inflam-
mation at the leading edge is one possible mechanism for pro-
gressive symptoms, and more diffuse injury might also play a
role.38 Histopathological studies in chronic MS show that focal
inflammatory changes, microglial activation, and astrocytosis
typically accompany axonopathy and myelin injury.39–41
Furthermore, chronic demyelination appears to predispose
axons to early death.42 In addition, ectopic B-cell–containing
immune aggregates located in the overlying meninges and in
Virchow–Robin perivascular spaces could contribute to pro-
gressive cortical injury. Thus, histopathological studies support
a model in which both microscopic and macroscopic tissue
injury occur with CNS inflammation.
These data also indicate that silent progression is not an
invariable accompaniment of RRMS, and that measurement
of whole brain atrophy might serve as a surrogate marker to
identify patients with insidiously progressive ongoing disabil-
ity. Incorporating a threshold for preservation of brain volume
was proposed as a component for no evidence of disease activ-
ity (NEDA-4).43 For fingolimod-treated patients, incorporat-
ing a minimal acceptable threshold for preservation of brain
volume reduced the proportion of patients meeting the
NEDA criteria from 31% for NEDA-3 to 19.7% for
NEDA-4, underscoring the remaining unmet need for thera-
pies that are more effective in arresting axonopathy and brain
volume loss than current treatments.
Regulatory agencies have approved more than a dozen
therapies for treatment of RRMS. All are proven, with vary-
ing degrees of efficacy, to reduce the occurrence of clinical
relapses and prevent development of focal lesions measured
on brain MRI. For the most part, the selection of which
treatment to use is based on these measures of efficacy as
well as consideration of safety and tolerability. Our observa-
tion that tissue injury distinct from focal white matter
lesions underlies long-term disability in RRMS suggests that
treatment selection should also consider the impact on silent
progression and on associated measures of brain atrophy.
Importantly, recent studies indicate that the high-efficacy
therapies natalizumab44 and ocrelizumab45 reduce progres-
sion independent of relapse activity in RRMS, although
these effects were partial. Additional studies are needed to
determine whether long-term benefits on disability preven-
tion are mediated by prevention of brain volume loss.
Our conclusions in regard to the impact of relapses on
long-term disability are consistent with those from the British
Columbia cohort7 but appear to diverge from the observations
from MSBase.13 One explanation for this difference could be
sample size. The MSBase group drew their conclusions from
a larger dataset of 2,466 relapsing onset participants and has
greater power to detect predictors of long-term disability with
small effect sizes. However, advantages of the current EPIC
study are its prospective ascertainment, systematic MRI acqui-
sition and analysis, and a high rate of retention that reduces
the impact of bias introduced by missing information from
participants lost to follow-up. The mean annual relapse
frequency was slightly higher in MSBase than EPIC (0.36
compared with 0.25, p < 0.001), possibly increasing the long-
term effect of attacks on disability. Differences in prescribing
practice between these datasets could also play a role, as treat-
ment likely influences not only relapse frequency but also
relapse severity. The methods used for assessing the impact of
relapses on long-term disability between these 2 studies are
also different; in EPIC we used a minimal threshold for dis-
ability worsening from our baseline observation and correlated
relapse occurrence with both short-term and long-term dis-
ability worsening, whereas MSBase used a linear-regression
model that considered the impact of the ARR over the
10 years of study on median 10-year EDSS change.
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The 16-year follow-up study of the pivotal inter-
feron β-1b trial46 also found an impact of relapses on
long-term disability. Participants in this study had higher
relapse rates (1.2 ARR) and baseline EDSS scores (3.0),
indicating that this cohort was more clinically active and
had worse disability compared to the EPIC dataset. At the
time of the pivotal interferon β-1b trial, therapeutic
options for escalation treatment were limited. Perhaps
even more importantly, these studies used different ana-
lytic methods: the interferon β-1b long-term follow-up
study assessed whether the ARR during the first 2 years of
the study correlated with increased EDSS by year 16.
When relapses have been correlated with long-term dis-
ability, their impact typically was observed primarily during
the first 2 to 5 years from disease onset.8–12 With earlier diag-
nosis of MS based on evolving diagnostic criteria and hence
earlier treatment, it seems likely that many patients with high
relapse frequency would be treated with disease-modifying
therapies, thereby attenuating the association between early
frequent relapses and long-term disability. Given that the
mean disease duration at baseline in the EPIC dataset was
7.6 years (see Table 1), the majority of the observations
regarding relapses in this dataset occur after the first 5 years of
disease onset. Therefore, due to differences in the windows of
observation, our finding that relapses do not contribute to
long-term disability may be consistent with these prior studies.
Lastly, our findings should not be interpreted to suggest that
MS relapses are without clinical significance. Within this
dataset, in addition to the impact of relapses on short-term
disability, there are circumstances in which severe relapses cau-
sed permanent disability (data not shown). Rather, our results
argue that long-term disability in RRMS is not primarily
driven by cumulative injury from relapses.
Our study has several limitations. We were not able
to identify a statistically significant impact of treatment on
long-term disability or brain volume loss; however, this
dataset is likely underpowered to detect small treatment
effects mediated through reduction of new white matter
lesions detected by MRI. In addition to the relatively small
size of our dataset, information on relapses was patient-
reported and thus is not directly comparable to clinician-
validated relapses obtained from controlled clinical trials.
In the clinical trial setting, participants are assessed within a
defined window of relapse onset, and relapses are defined by
an objective change in EDSS score. Such rigorous relapse
assessment was beyond the scope of our study, which was
designed for long-term characterization of the MS phenotype.
We therefore relied on patient-reported relapses that were
assessed through structured interview. When our participants
were clustered by factor analysis of mixed data (see Fig 2), par-
ticipants with the same relapse frequency grouped together,
suggesting validity of self-reported relapses. Moreover, in the
CombiRx study, the impact of treatment on patient-reported
relapses was similar to that of protocol-defined relapses,
suggesting that patient-reported relapses are likely valid.47
Another potential limitation is the possibility that focal gray
matter lesions or spinal cord lesions, not quantified in this
study, could contribute to long-term disability. Finally, results
obtained from any single-center design may not be replicated
in other datasets. Work is underway to address this issue; we
have partnered with other groups who have similar deeply
phenotyped long-term datasets for the purpose of increasing
statistical power and performing validation studies for these
and other observations.48 Despite these limitations, the char-
acteristics of this dataset are consistent with previously publi-
shed observations in that MS relapses were associated with
new lesions on brain MRI and were associated with increased
short-term MS disability.2,3 The consistency of our findings
regarding short-term outcomes lends credence to our longer-
term observations.
In summary, the high degree of effectiveness of MS
therapies against clinical attacks and new white matter lesions
made it possible to prospectively assess long-term outcomes in
RRMS when these elements of focal disease were silenced.
The appearance of silent progression during the RRMS phase
and its association with brain atrophy suggest that the same
process that underlies SPMS likely begins far earlier than is
generally recognized and support a unitary view of MS biol-
ogy, with both focal and diffuse tissue destructive components,
and with inflammation and neurodegeneration occurring
throughout the disease spectrum. In addition to brain atrophy,
other markers of neural degeneration, such as quantitative spi-
nal cord imaging,49 optical coherence tomography,50 and
serum neurofilament light chains,51 may also prove useful in
identifying patients with silent progression. Moreover, as
relapses and focal white matter lesions are brought under
excellent control by disease-modifying therapies for RRMS,
the effectiveness of these agents against silent progression is
likely to represent a key determinant of their relative value.
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